PAH and cancer cells share similar proliferating phenotypes [31], [32], [33], and the overexpression of EZH2 is directly responsible for the de novo suppression of multiple genes in human cancer [14], [29], [30], [34] and is a known pathogenic factor in breast and prostate cancer [34]. Here, EZH2 is linked to pulmonary arterial hypertension.